Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
30 June 2021
Deals | France | Corporate/M&A
Gide has advised Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells and best-in-class manufacturing, for its € 75 Million series A fund raising.
The Series A financing was led by Casdin Capital, returning investor Sofinnova Partners, and an undisclosed investor, including participation from Redmile, Emerson Collective and Alexandria Venture Investments.
The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center (MSK).
Gide's team advising Mnemo Therapeutics comprised partner David-James Sebag, working with counsel Paul-Jourdan Nayrac and associate Mathilde Faure.
Goodwin advised the investors (Thomas Dupont-Sentilles).
